Carisma Therapeutics’ (CARM) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM) in a research note published on Monday morning,Benzinga reports. The firm currently has a $12.00 price objective on the stock.

CARM has been the topic of several other research reports. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. Evercore ISI reissued an “in-line” rating and issued a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Finally, Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $10.00 to $1.00 in a report on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $4.94.

Carisma Therapeutics Stock Down 2.0 %

Shares of NASDAQ CARM opened at $0.45 on Monday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.77. The firm has a market capitalization of $18.60 million, a PE ratio of -0.29 and a beta of 1.56. The firm has a fifty day simple moving average of $0.67 and a two-hundred day simple moving average of $0.92.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The business had revenue of $3.39 million during the quarter. Equities analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Institutional Investors Weigh In On Carisma Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Wexford Capital LP lifted its holdings in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics during the 2nd quarter valued at $40,000. Finally, Barclays PLC lifted its holdings in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.